US5407914A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pulmonary surfactant protein and related polypeptides
Assignee: Scripps Research Institute
•
Filing: 1993-05-12
•
Granted: 1995-04-18
•
Expires: 2013-05-12
Abstract
Abstract The present invention discloses useful peptides and synthetic pulmonary surfactants, as well as methods of making and using same. In a preferred embodiment, a synthetic pulmonary surfactant comprises one or more pharmaceutically acceptable phospholipids admixed with a polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions. In other embodiments, a surfactant peptide has an amino acid residue sequence selected from the group consisting of KLLLLKLLLLKLLLLKLLLLK, KLLLLLLLLKLLLLLLLLKLL, and KKLLLLLLLKKLLLLLLLKKL.
Inventors
- 👤 Charles G. Cochrane
- 👤 Susan D. Revak
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 05:47
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/785; A; A61; A61P; A61P11/00; A61K; A61K38/00
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
147 words
A synthetic pulmonary surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula (Z a U b ) c Z d , wherein: Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K; U is a hydrophobic amino acid residue independently selected from the group consisting of L and C; a is 1 or 2; b has an average value of about 3 to about 8; c is 1 to 10; and d is 0 to 2; said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.
Claim 2
Dependent Claim
147 words
A synthetic pulmonary surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula (Z a U b ) c Z d , wherein: Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K; U is a hydrophobic amino acid residue independently selected from the group consisting of L and C; a is 1 or 2; b has an average value of about 3 to about 8; c is 1 to 10; and d is 0 to 2; said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.
Claim 3
Dependent Claim
20 words
The synthetic pulmonary surfactant of claim 1, said polypeptide having an amino acid residue sequence represented by the formula: KLLLLKLLLLKLLLLKLLLLK.
Claim 4
Dependent Claim
20 words
The synthetic pulmonary surfactant of claim 1, said polypeptide having an amino acid residue sequence represented by the formula: KLLLLLLLLKLLLLLLLLKLL.
Claim 5
Dependent Claim
20 words
The synthetic pulmonary surfactant of claim 1, said polypeptide having an amino acid residue sequence represented by the formula: KKLLLLLLLKKLLLLLLLKKL.
Claim 6
Dependent Claim
53 words
A synthetic pulmonary surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having an amino acid residue sequence represented by the formula: KLLLLKLLLLKLLLLKLLLLK, said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.
Claim 7
Dependent Claim
53 words
A synthetic pulmonary surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having an amino acid residue sequence represented by the formula: KLLLLKLLLLKLLLLKLLLLK, said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.
Claim 8
Dependent Claim
18 words
A polypeptide having an amino acid residue sequence selected from the group consisting of: KLLLLKLLLLKLLLLKLLLLK, KLLLLLLLLKLLLLLLLLKLL, and KKLLLLLLLKKLLLLLLLKKL.
Claim 9
Dependent Claim
18 words
A polypeptide having an amino acid residue sequence selected from the group consisting of: KLLLLKLLLLKLLLLKLLLLK, KLLLLLLLLKLLLLLLLLKLL, and KKLLLLLLLKKLLLLLLLKKL.
Claim 10
Dependent Claim
34 words
A polypeptide according to claim 6, wherein said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forms a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.
Claim 11
Independent Claim
142 words
A method of treating respiratory distress syndrome comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant, said surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having alternating hydrophobic and hydrophilic amino acid residue regions, represented by the formula (Z a U b ) c Z d , wherein: Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K; U is a hydrophobic amino acid residue independently selected from the group consisting of L and C; a is 1 or 2; b has an average value of about 3 to about 8; c is 1 to 10; and d is 0 to 2; said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.
Claim 12
Independent Claim
142 words
A method of treating respiratory distress syndrome comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant, said surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having alternating hydrophobic and hydrophilic amino acid residue regions, represented by the formula (Z a U b ) c Z d , wherein: Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K; U is a hydrophobic amino acid residue independently selected from the group consisting of L and C; a is 1 or 2; b has an average value of about 3 to about 8; c is 1 to 10; and d is 0 to 2; said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.
Claim 13
Dependent Claim
19 words
The method of claim 8, wherein said polypeptide has an amino acid residue sequence represented by the formula: KLLLLKLLLLKLLLLKLLLLK.
Claim 14
Dependent Claim
19 words
The method of claim 8, wherein said polypeptide has an amino acid residue sequence represented by the formula: KLLLLLLLLKLLLLLLLLKLL.
Claim 15
Dependent Claim
19 words
The method of claim 8, wherein said polypeptide has an amino acid residue sequence represented by the formula: KKLLLLLLLKKLLLLLLLKKL.
Claim 16
Independent Claim
69 words
A method of treating respiratory distress syndrome comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant, said surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having an amino acid residue sequence represented by the formula: KLLLLKLLLLKLLLLKLLLLK, said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.
Claim 17
Independent Claim
69 words
A method of treating respiratory distress syndrome comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant, said surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having an amino acid residue sequence represented by the formula: KLLLLKLLLLKLLLLKLLLLK, said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.
References Cited (Backward Citations)
US4643988A
Cited
US4562003A
Cited
US4656253A
Cited
WO1986003408A1
Cited
WO1987006588A1
Cited
WO1988003170A1
Cited
WO1989006657A1
Cited
US5260273A
Cited
US4861756A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-04-17 | 1998-10-17 | 1999-04-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-04-17 | 2002-10-17 | 2003-04-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-04-17 | 2006-10-17 | 2007-04-18 | $7700.00 | Window Closed / Lapsed |